Literature DB >> 23427088

In vivo overexpression of tissue-nonspecific alkaline phosphatase increases skeletal mineralization and affects the phosphorylation status of osteopontin.

Sonoko Narisawa1, Manisha C Yadav, José Luis Millán.   

Abstract

Functional ablation of tissue-nonspecific alkaline phosphatase (TNAP) (Alpl⁻/⁻ mice) leads to hypophosphatasia, characterized by rickets/osteomalacia attributable to elevated levels of extracellular inorganic pyrophosphate, a potent mineralization inhibitor. Osteopontin (OPN) is also elevated in the plasma and skeleton of Alpl⁻/⁻ mice. Phosphorylated OPN is known to inhibit mineralization, however, the phosphorylation status of the increased OPN found in Alpl⁻/⁻ mice is unknown. Here, we generated a transgenic mouse line expressing human TNAP under control of an osteoblast-specific Col1a1 promoter (Col1a1-Tnap). The transgene is expressed in osteoblasts, periosteum, and cortical bones, and plasma levels of TNAP in mice expressing Col1a1-Tnap are 10 to 20 times higher than those of wild-type mice. The Col1a1-Tnap animals are healthy and exhibit increased bone mineralization by micro-computed tomography (µCT) analysis. Crossbreeding of Col1a1-Tnap transgenic mice to Alpl⁻/⁻ mice rescues the lethal hypophosphatasia phenotype characteristic of this disease model. Osteoblasts from [Col1a1-Tnap] mice mineralize better than nontransgenic controls and osteoblasts from [Col1a1-Tnap⁺/⁻; Alpl⁻/⁻] mice are able to mineralize to the level of Alpl⁺/⁻ heterozygous osteoblasts, whereas Alpl⁻/⁻ osteoblasts show no mineralization. We found that the increased levels of OPN in bone tissue of Alpl⁻/⁻ mice are comprised of phosphorylated forms of OPN whereas wild-type (WT) and [Col1a1-Tnap⁺/⁻; Alpl⁻/⁻] mice had both phosphorylated and dephosphorylated forms of OPN. OPN from [Col1a1-Tnap] osteoblasts were more dephosphorylated than nontransgenic control cells. Titanium dioxide-liquid chromatography and tandem mass spectrometry analysis revealed that OPN peptides derived from Alpl⁻/⁻ bone and osteoblasts yielded a higher proportion of phosphorylated peptides than samples from WT mice, and at least two phosphopeptides, p(S¹⁷⁴FQVS¹⁷⁸DEQY¹⁸²PDAT¹⁸⁶DEDLT¹⁹¹)SHMK and FRIp(S²⁹⁹HELES³⁰⁴S³⁰⁵S³⁰⁶S³⁰⁷)EVN, with one nonlocalized site each, appear to be preferred sites of TNAP action on OPN. Our data suggest that the promineralization role of TNAP may be related not only to its accepted pyrophosphatase activity but also to its ability to modify the phosphorylation status of OPN.
Copyright © 2013 American Society for Bone and Mineral Research.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23427088      PMCID: PMC3688694          DOI: 10.1002/jbmr.1901

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  45 in total

Review 1.  Physiological role of alkaline phosphatase explored in hypophosphatasia.

Authors:  Michael P Whyte
Journal:  Ann N Y Acad Sci       Date:  2010-03       Impact factor: 5.691

2.  Separation and detection of large phosphoproteins using Phos-tag SDS-PAGE.

Authors:  Eiji Kinoshita; Emiko Kinoshita-Kikuta; Tohru Koike
Journal:  Nat Protoc       Date:  2009-09-24       Impact factor: 13.491

Review 3.  Osteopontin function in pathology: lessons from osteopontin-deficient mice.

Authors:  S R Rittling; D T Denhardt
Journal:  Exp Nephrol       Date:  1999 Mar-Apr

4.  Post-translationally modified residues of native human osteopontin are located in clusters: identification of 36 phosphorylation and five O-glycosylation sites and their biological implications.

Authors:  Brian Christensen; Mette S Nielsen; Kim F Haselmann; Torben E Petersen; Esben S Sørensen
Journal:  Biochem J       Date:  2005-08-15       Impact factor: 3.857

5.  Linked deficiencies in extracellular PP(i) and osteopontin mediate pathologic calcification associated with defective PC-1 and ANK expression.

Authors:  Kristen Johnson; James Goding; Deborah Van Etten; Adnan Sali; Shou-Ih Hu; David Farley; Hollis Krug; Lovisa Hessle; José Luis Millán; Robert Terkeltaub
Journal:  J Bone Miner Res       Date:  2003-06       Impact factor: 6.741

6.  Modulation of crystal formation by bone phosphoproteins: structural specificity of the osteopontin-mediated inhibition of hydroxyapatite formation.

Authors:  G K Hunter; C L Kyle; H A Goldberg
Journal:  Biochem J       Date:  1994-06-15       Impact factor: 3.857

7.  Tissue-nonspecific alkaline phosphatase and plasma cell membrane glycoprotein-1 are central antagonistic regulators of bone mineralization.

Authors:  Lovisa Hessle; Kristen A Johnson; H Clarke Anderson; Sonoko Narisawa; Adnan Sali; James W Goding; Robert Terkeltaub; José Luis Millan
Journal:  Proc Natl Acad Sci U S A       Date:  2002-06-24       Impact factor: 11.205

8.  Enzyme replacement therapy for murine hypophosphatasia.

Authors:  José Luis Millán; Sonoko Narisawa; Isabelle Lemire; Thomas P Loisel; Guy Boileau; Pierre Leonard; Svetlana Gramatikova; Robert Terkeltaub; Nancy Pleshko Camacho; Marc D McKee; Philippe Crine; Michael P Whyte
Journal:  J Bone Miner Res       Date:  2008-06       Impact factor: 6.741

9.  Enzyme replacement therapy prevents dental defects in a model of hypophosphatasia.

Authors:  M D McKee; Y Nakano; D L Masica; J J Gray; I Lemire; R Heft; M P Whyte; P Crine; J L Millán
Journal:  J Dent Res       Date:  2011-01-06       Impact factor: 6.116

10.  Loss of skeletal mineralization by the simultaneous ablation of PHOSPHO1 and alkaline phosphatase function: a unified model of the mechanisms of initiation of skeletal calcification.

Authors:  Manisha C Yadav; Ana Maria Sper Simão; Sonoko Narisawa; Carmen Huesa; Marc D McKee; Colin Farquharson; José Luis Millán
Journal:  J Bone Miner Res       Date:  2010-08-03       Impact factor: 6.741

View more
  48 in total

1.  Osteopontin regulates dentin and alveolar bone development and mineralization.

Authors:  B L Foster; M Ao; C R Salmon; M B Chavez; T N Kolli; A B Tran; E Y Chu; K R Kantovitz; M Yadav; S Narisawa; J L Millán; F H Nociti; M J Somerman
Journal:  Bone       Date:  2017-12-05       Impact factor: 4.398

2.  A GTPase-activating protein-binding protein (G3BP1)/antiviral protein relay conveys arteriosclerotic Wnt signals in aortic smooth muscle cells.

Authors:  Bindu Ramachandran; John N Stabley; Su-Li Cheng; Abraham S Behrmann; Austin Gay; Li Li; Megan Mead; Julia Kozlitina; Andrew Lemoff; Hamid Mirzaei; Zhijian Chen; Dwight A Towler
Journal:  J Biol Chem       Date:  2018-04-06       Impact factor: 5.157

3.  Multilineage somatic activating mutations in HRAS and NRAS cause mosaic cutaneous and skeletal lesions, elevated FGF23 and hypophosphatemia.

Authors:  Young H Lim; Diana Ovejero; Jeffrey S Sugarman; Cynthia M C Deklotz; Ann Maruri; Lawrence F Eichenfield; Patrick K Kelley; Harald Jüppner; Michael Gottschalk; Cynthia J Tifft; Rachel I Gafni; Alison M Boyce; Edward W Cowen; Nisan Bhattacharyya; Lori C Guthrie; William A Gahl; Gretchen Golas; Erin C Loring; John D Overton; Shrikant M Mane; Richard P Lifton; Moise L Levy; Michael T Collins; Keith A Choate
Journal:  Hum Mol Genet       Date:  2013-09-04       Impact factor: 6.150

Review 4.  Molecular and cellular aspects of calcific aortic valve disease.

Authors:  Dwight A Towler
Journal:  Circ Res       Date:  2013-07-05       Impact factor: 17.367

5.  Overlapping functions of bone sialoprotein and pyrophosphate regulators in directing cementogenesis.

Authors:  M Ao; M B Chavez; E Y Chu; K C Hemstreet; Y Yin; M C Yadav; J L Millán; L W Fisher; H A Goldberg; M J Somerman; B L Foster
Journal:  Bone       Date:  2017-09-01       Impact factor: 4.398

Review 6.  Osteogenesis imperfecta and therapeutics.

Authors:  Roy Morello
Journal:  Matrix Biol       Date:  2018-03-11       Impact factor: 11.583

Review 7.  Nutrition in Cardioskeletal Health.

Authors:  Kathleen M Hill Gallant; Connie M Weaver; Dwight A Towler; Sowmyanarayanan V Thuppal; Regan L Bailey
Journal:  Adv Nutr       Date:  2016-05-16       Impact factor: 8.701

8.  Skeletal Mineralization Deficits and Impaired Biogenesis and Function of Chondrocyte-Derived Matrix Vesicles in Phospho1(-/-) and Phospho1/Pi t1 Double-Knockout Mice.

Authors:  Manisha C Yadav; Massimo Bottini; Esther Cory; Kunal Bhattacharya; Pia Kuss; Sonoko Narisawa; Robert L Sah; Laurent Beck; Bengt Fadeel; Colin Farquharson; José Luis Millán
Journal:  J Bone Miner Res       Date:  2016-05-17       Impact factor: 6.741

9.  Tissue-nonspecific alkaline phosphatase deficiency causes abnormal craniofacial bone development in the Alpl(-/-) mouse model of infantile hypophosphatasia.

Authors:  Jin Liu; Hwa Kyung Nam; Cassie Campbell; Kellen Cristina da Silva Gasque; José Luis Millán; Nan E Hatch
Journal:  Bone       Date:  2014-07-09       Impact factor: 4.398

10.  Increased osteopontin contributes to inhibition of bone mineralization in FGF23-deficient mice.

Authors:  Quan Yuan; Yan Jiang; Xuefeng Zhao; Tadatoshi Sato; Michael Densmore; Christiane Schüler; Reinhold G Erben; Marc D McKee; Beate Lanske
Journal:  J Bone Miner Res       Date:  2014-03       Impact factor: 6.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.